http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 07:36:58 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Immunocore+Holdings+%28IMCR%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26759860.html <p>Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Immunocore Holdings (NASDAQ: IMCR).</p><p>The analyst commented, "Immunocore is finishing up enrollment in TEBE-AM, its Ph3 study of tebentafusp (Kimmtrak, a gp100-targeted TCR bispecific) in 2L cutaneous melanoma. To our knowledge, this is the first randomized post-checkpoint cutaneous melanoma (CM) study with an overall survival primary endpoint. We see a remarkable risk/reward in IMCR shares around this readout. The downside valuation support is meaningful. Kimmtrak in metastatic uveal melanoma (mUM) is annalizing at >$400M/yr, with >98% gross margins and IP to 2035 or longer. We think the established mUM business alone http://www.streetinsider.com/Analyst+Comments/Immunocore+Holdings+%28IMCR%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26759860.html Mon, 13 Jul 2026 07:36:58 -0400 IMCR http://www.streetinsider.com/FDA/Immunocore+reports+Phase+1+trial+results+for+melanoma+treatment+brenetafusp/26577385.html <p>Immunocore Holdings plc (NASDAQ: IMCR) released updated Phase 1 data for brenetafusp in patients with heavily pretreated advanced melanoma at the 2026 American Society of Clinical Oncology Annual Meeting.</p> <p>In 66 patients treated with brenetafusp monotherapy, the median overall survival was 14.3 months with a 6-month overall survival rate of 87% and a disease control rate of 52%. The overall response rate was 12%. Patients received target doses ranging from 20-320 mcg.</p> <p>Clinical benefit measures were numerically higher for patients treated with the 160 mcg dose compared to 40 mcg, despite worse baseline prognostic factors. These results support the selection of 160 http://www.streetinsider.com/FDA/Immunocore+reports+Phase+1+trial+results+for+melanoma+treatment+brenetafusp/26577385.html Sun, 31 May 2026 08:00:18 -0400 IMCR http://www.streetinsider.com/Press+Releases/Immunocore+presents+updated+Phase+1+data+of+brenetafusp+in+patients+with+heavily+pretreated+advanced+melanoma/26577380.html <p align="center"><b>Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma</b></p> <p align="center"><i>Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma</i></p> <p align="center"><i>Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma</i></p> <p align="center"><i>Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance</i></p> <p align="center"><i>Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab</i></p> <p align="left">(OXFORDSHIRE, England &amp; RADNOR, Penn. &amp; GAITHERSBURG, http://www.streetinsider.com/Press+Releases/Immunocore+presents+updated+Phase+1+data+of+brenetafusp+in+patients+with+heavily+pretreated+advanced+melanoma/26577380.html Sun, 31 May 2026 08:00:00 -0400 IMCR http://www.streetinsider.com/Globe+Newswire/Immunocore+presents+updated+Phase+1+data+of+brenetafusp+in+patients+with+heavily+pretreated+advanced+melanoma/26577380.html <p align="center"><b>Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma</b></p> <p align="center"><i>Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma</i></p> <p align="center"><i>Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma</i></p> <p align="center"><i>Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance</i></p> <p align="center"><i>Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab</i></p> <p align="left">(OXFORDSHIRE, England &amp; RADNOR, Penn. &amp; GAITHERSBURG, http://www.streetinsider.com/Globe+Newswire/Immunocore+presents+updated+Phase+1+data+of+brenetafusp+in+patients+with+heavily+pretreated+advanced+melanoma/26577380.html Sun, 31 May 2026 08:00:00 -0400 IMCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Bell+John+Irving/26569329.html si-local-file:///var/storage/secattach/20260528/26569329.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Bell+John+Irving/26569329.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Bell+John+Irving/26569329.html si-local-file:///var/storage/secattach/20260528/26569329.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Bell+John+Irving/26569329.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Herbst+Roy+Steven/26569330.html si-local-file:///var/storage/secattach/20260528/26569330.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Herbst+Roy+Steven/26569330.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Herbst+Roy+Steven/26569330.html si-local-file:///var/storage/secattach/20260528/26569330.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Herbst+Roy+Steven/26569330.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Kaul+Siddharth/26569331.html si-local-file:///var/storage/secattach/20260528/26569331.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Kaul+Siddharth/26569331.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Kaul+Siddharth/26569331.html si-local-file:///var/storage/secattach/20260528/26569331.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Kaul+Siddharth/26569331.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Ratcliffe+Peter+John/26569332.html si-local-file:///var/storage/secattach/20260528/26569332.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Ratcliffe+Peter+John/26569332.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Ratcliffe+Peter+John/26569332.html si-local-file:///var/storage/secattach/20260528/26569332.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Ratcliffe+Peter+John/26569332.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Peterson+Kristine/26569333.html si-local-file:///var/storage/secattach/20260528/26569333.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Peterson+Kristine/26569333.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Peterson+Kristine/26569333.html si-local-file:///var/storage/secattach/20260528/26569333.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Peterson+Kristine/26569333.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Pao+William/26569334.html si-local-file:///var/storage/secattach/20260528/26569334.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Pao+William/26569334.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Pao+William/26569334.html si-local-file:///var/storage/secattach/20260528/26569334.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immunocore+Holdings+plc+++For%3A+May+27++Filed+by%3A+Pao+William/26569334.html Thu, 28 May 2026 19:55:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunocore+Holdings+plc+++For%3A+May+27/26558217.html si-local-file:///var/storage/secattach/20260527/26558217.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunocore+Holdings+plc+++For%3A+May+27/26558217.html Wed, 27 May 2026 16:22:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunocore+Holdings+plc+++For%3A+May+27/26558217.html si-local-file:///var/storage/secattach/20260527/26558217.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immunocore+Holdings+plc+++For%3A+May+27/26558217.html Wed, 27 May 2026 16:22:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Berman+David+M/26541271.html si-local-file:///var/storage/secattach/20260522/26541271.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Berman+David+M/26541271.html Fri, 22 May 2026 15:44:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Berman+David+M/26541271.html si-local-file:///var/storage/secattach/20260522/26541271.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Berman+David+M/26541271.html Fri, 22 May 2026 15:44:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Berman+David+M/26534191.html si-local-file:///var/storage/secattach/20260521/26534191.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Berman+David+M/26534191.html Thu, 21 May 2026 13:57:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Berman+David+M/26534191.html si-local-file:///var/storage/secattach/20260521/26534191.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Berman+David+M/26534191.html Thu, 21 May 2026 13:57:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507592.html si-local-file:///var/storage/secattach/20260515/26507592.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507592.html Fri, 15 May 2026 17:04:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507592.html si-local-file:///var/storage/secattach/20260515/26507592.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+Vestal+Point+Capital%2C+LP/26507592.html Fri, 15 May 2026 17:04:00 -0400 IMCR O.49410575 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26501260.html si-local-file:///var/storage/secattach/20260515/26501260.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Immunocore+Holdings+plc++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26501260.html Fri, 15 May 2026 10:07:00 -0400 IMCR O.49410575